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ABSTRACT
Purpose: Neutrophilia is hallmark of classic Hodgkin Lymphoma (cHL), 
but its precise characterization remains elusive. We aimed at investigating the 
immunosuppressive role of high-density neutrophils in HL.
Experimental design: First, N-HL function was evaluated in vitro, showing 
increased arginase (Arg-1) expression and activity compared to healthy subjects. 
Second, we measured serum level of Arg-1 (s-Arg-1) by ELISA in two independent, 
training (N = 40) and validation (N = 78) sets.
Results: s-Arg-1 was higher in patients with advanced stage (p = 0.045), 
B-symptoms (p = 0.0048) and a positive FDG-PET scan after two cycles of 
chemotherapy (PET-2, p = 0.012). Baseline levels of s-Arg-1 > 200 ng/mL resulted 
in 92% sensitivity and 56% specificity to predict a positive PET-2.
Patients showing s-Arg-1 levels > 200 ng/mL had a shorter progression free 
survival (PFS). In multivariate analysis, PET-2 and s-Arg-1 at diagnosis were the only 
statistically significant prognostic variables related to PFS (respectively p = 0.0004 
and p = 0.012).
Moving from PET-2 status and s-Arg-1 level we constructed a prognostic score 
to predict long-term treatment outcome: low s-Arg-1 and negative PET-2 scan (score 
0, N = 63), with a 3-Y PFS of 89.5%; either positive PET-2 or high s-Arg-1 (score 1, 
N = 46) with 3-Y PFS of 67.6%, and both positive markers (score 2, N = 9) with a 
3-Y PFS of 37% (p = 0.0004). 
Conclusions: We conclude that N-HL are immunosuppressive through increased 
Arg-1 expression, a novel potential biomarker for HL prognosis.
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INTRODUCTION
Hodgkin Lymphoma (HL) is a neoplastic disorder 
characterized by a peculiar tumour architecture with few, 
scattered neoplastic cells surrounded by accessory non-
neoplastic reactive cells [1, 2]. These accessory cells are 
responsible for the persistent 18F-Fuoro-2-Deoxy-Glucose 
(FDG) uptake in positron emission tomography (PET) scan 
performed early after first two cycles of chemotherapy 
(PET-2) [3–6]. Currently, a positive PET-2 is the main 
predictor of standard treatment outcome in HL and, 
accordingly, clinical trials incorporating PET-2 in a risk-
adapted strategy have shown promising results [7, 8]. Other 
clinically relevant prognostic factors in advanced-stage HL 
include the international prognostic score (IPS) [9], recently 
validated in a series of advanced-stage patients treated with 
ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) 
regimen [10] and the amount of tumour-associated 
macrophages (TAM) in the diagnostic biopsy [11].
Several studies have documented the prognostic 
role of a subset of myeloid cells, defined as “myeloid-
derived suppressor cells” (MDSC) in several solid and 
haematological cancers. MDSC phenotype in humans is still 
controversial [12–16]. Our previous work found that MDSC 
are increased in HL and have a prognostic significance [17]. 
MDSC are a heterogeneous set of myeloid cells 
at different stage of maturation that eventually evolve 
to the stage of neutrophils with a phenotype largely 
overlapping that of the granulocytic series [18, 19]. 
MDSC exert an enforced immune suppressive function 
against T-lymphocytes, arising from high expression of 
arginase (Arg-1) [20–23]. In mature neutrophils, Arg-
1 is constitutively produced and stocked in cytoplasmic 
azurrophil granules [24–26] to be readily released during 
inflammation, to deplete the milieu of arginine [22].
Arg-1 metabolizes L-arginine to L-ornithine and 
urea in cytosol [22]. In T-cells, Arg-1 induces depletion of 
arginine from the microenvironment, an essential amino 
acid for the effective function of T-cell receptor (TCR) 
zeta chain assembly and downstream signalling [23, 27] 
as a consequence, L-arginine depletion profoundly 
suppresses T cell immune responses and this has emerged 
as a fundamental mechanism of inflammation-associated 
immunosuppression [19, 28–31]. 
Since both leucocytosis and lymphopenia have 
been incorporated in IPS because prognostically relevant 
[9], we explored the functional activity of neutrophils in 
HL (HL-N), their relation with disease burden and the 
prognostic value of their product, Arg-1.
RESULTS
Neutrophils are dysfunctional and 
immunesuppressive in HL
Phagocytic activity was reduced in HL-N at 
diagnosis compared to healthy subjects (Figure 1A). 
In order to understand if this finding was due 
to a persistence or lack of activation we investigated 
the neutrophil activation marker CD11b, because it 
promotes the phagocytosis of iC3b-coated particles and 
its expression increases rapidly following phagocyte 
activation. The MFI of the activation marker CD11b 
on HL-N was higher than CTRL-N (N = 40, 25.3 ± 1.3 
versus 15.6 ± 0.8 au, p < 0.0001, Figure 1B) and reduced 
up to normal values after two courses of chemotherapy 
(as shown in 15 patients, 26.5 ± 1.1 versus 16.5 ± 1.0, p = 
0.0002, Figure 1C). 
In order to detect if a soluble factor, HL related, 
could explain these changes in N, we incubated for 24 
hours 4 CTRL-N with serum obtained from HL or healthy 
donors and we observed that HL serum induced an 
increase of CD11b MFI (p = 0.02, Figure 1D).
Lymphocytes isolated from 5 healthy subjects (h-
Ly) were co-cultured with neutrophils isolated from fresh 
peripheral blood of 8 HL patients (HL-N) and 5 healthy 
subjects (CTRL-N) in order to evaluate markers of 
activation after stimulation with PHA-P up to 72 hours 
in six independent experiments. In presence of HL-N, 
proliferation of T-cells was inhibited, in a dose-dependent 
manner (Supplementary Figure 2A). Similarly, despite 
PHA-P stimulation for 48 hours, CD69, CD71, HLA-
DR and CD3ζ expression in h-Ly remained low after 
co-culture with HL-N, but not with CRTL-N, in a dose-
dependent manner by increasing the ratio from 1:2 to 1:4 
to 1:8 (Supplementary Figure 2B–2E). Treatment with 200 
μM nor-NOHA (an Arg-1 inhibitor) for 48 hours reverted 
significantly this immunosuppressive effect, both at level 
of activation marker expression (Figure 2A–2C) and T-cell 
proliferation (Figure 2D).
Arg-1 is increased in HL patients
Basic characteristics and treatments of both sets 
of patients are summarized in Table 1. Median age was 
33 years (range 18–74) in the training set and 37 years 
(range 16–68) in the validation set. In both sets, most 
patients had advanced disease (Ann-Arbor stage ≥ IIB) 
and nodular sclerosis histotype. All except 5 had a history 
of infectious mononucleosis with positive antibody titre to 
the EBV viral capsid antigen.
By RT-PCR, we measured ARG-1 in white blood 
cells (PBWC) and we found a marked increase of Arg- 1 
expression of HL samples, almost entirely sustained by 
neutrophils (Figure 3A). Western blot of proteins obtained 
from HL-N confirmed this observation (Figure 3B). 
Neutrophils from HL patients showed also increased arginase 
activity in comparison to healthy subjects (Figure 3C). 
To link the neutrophil dysfunction found in 
the peripheral blood of HL patients with the peculiar 
immunological milieu of the disease, we investigated the 
expression of Arg-1 in situ. Within the HL microenvironment, 
Arg-1-expressing cells with granulocytic and monocytic 
morphology were found intermingling with malignant cells 
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(Figure 3D–3E). Arg-1+ cells were significantly enriched 
in HL tissue samples as compared with control reactive 
lymph node samples, in which only few scattered Arg-1-
expressing elements were found within T-cell rich areas 
(Figure 3F). The myeloid lineage of Arg-1+ cells infiltrating 
HL were confirmed by double immunofluorescence 
analysis with CD68, clone KP1, which highlights myelo-
monocytic elements (Figure 3G, upper panels). Moreover, 
the suppressor phenotype of Arg-1+ myeloid elements 
within HL microenvironment was also supported by double 
immunofluorescence for indoleamine 2,3-dioxygenase IDO 
(an enzyme acting as immune modulator through suppression 
of T-cell immunity, highly expressed in HL microenvironment 
and associated to poor outcome [32] which revealed that 
Arg-1+ cells also expressed IDO (Figure 3G, lower panels). 
Intensity of Arg-1 was independent from CD68 staining and 
clinical variables in the training set (data not shown). 
When we measured circulating Arg-1 in the serum 
of an enlarged cohort of patients (training+validation sets), 
we found it was increased in HL patients at diagnosis 
compared to healthy volunteers, mean ± standard deviation 
(SD) 174.6 ± 10.3 versus 51.5 ± 4.9 ng/mL (N = 118, 
p < 0.0001, Figure 4A). During and after standard first-line 
ABVD therapy Arg-1 was reduced: 78.6 ± 5.8 ng/mL after 
two cycles and 46.7 ± 3.4 ng/mL at the end of the planned 
cycles (Figure 4B, ANOVA p < 0.0001). 
We then correlated the measurement of Arg- 1 
in the serum at diagnosis with clinical findings. We 
found that patients with positive PET-2 showed higher 
Arg-1 at diagnosis compared to those who carried a 
negative PET2 (147.2 ± 9.1 versus 309.1 ± 25.8 ng/ mL, 
p < 0.0001, Figure 4C). Similarly, patients who 
achieved complete remission exhibited lower levels of 
Arg-1 compared to relapsed/refractory ones at diagnosis 
Table 1: Patients’ characteristics
Training set 
N = 40 (100%)
Validation set 
N = 78 (100%) p-value
Median age (range) 33 (18–74) 37 (16–68)
Sex (M/F) 24/16 48/30 0.98
Bulky disease (Yes/No) 11/29 11/67 0.08
B-symptoms present (Yes/No) 25/15 46/32 0.84
Lymphocyte count/10^3uL median (range) 1.33 ± 0.15 1.38 ± 0.31 0.51
Neutrophil count/10^3uL median (range) 8.58 ± 1.81 8.89 ± 1.63 0.35
Ann Arbor stage
Early disease 9 (22.5) 28 (35.9) 0.14
Advanced disease 31 (77.5) 50 (64.1)
Hystotype
Nodular sclerosis (%) 30 (75) 60 (77.5)
Mixed cellularity (%) 3 (7.5) 9 (12.5)
Lymphocyte-rich (%) 7 (17.5) 6 (7.5)
Lymphocyte-depleted (%) 0 (0) 3 (2.5)
IPS (only for advanced stage)
< 2 5 19 0.04
2–7 26 29
LDH median (range) 386 ± 56 397 ± 47 0.26
ESR median (range) 45 ± 23 52 ± 31 0.21
Treatment
ABVD 2 cycles ± i.f. radiotherapy
ABVD 4 cycles ± i.f. radiotherapy
ABVD 6 cycles
ABVD 2 cycles + BEACOPP 8 cycles
3 (7.5)
3 (7.5)
29 (72.5)
5 (12.5)
2 (2.5)
26 (33.5)
41 (52.5)
9 (11.5)
Clinical features of patients at baseline and their first-line treatment.
Abbreviations: LDH: lactico-dehydrogenase, ESR: Erythrocyte Sedimentation Rate, C-RP: C-Reactive Protein; i.f. involved 
field.
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(149.2 ± 9.4 versus 269.2 ± 26.1 ng/mL, p < 0.0001, 
Figure 4D).
Arg-1 was increased in patients with advanced 
disease, B-symptoms, and elevated ESR in early-stage 
patients as shown in Supplementary Figure 3 for both 
training and validation sets.
High Arg-1 amount is associated to shorter PFS
In the training set, 9/40 (22.5%) patients had 
s-Arg-1 at diagnosis higher than 200 ng/ml, and six of 
them had positive PET-2 and were addressed to an early 
salvage therapy accordingly to BEACOPP scheme, 3/6 
achieving complete remission. A level of 200 ng/mL Arg-1 
resulted in 87% (95% C.I. 71–96) sensitivity and 62% 
(95% C.I. 25–92) specificity in predicting achievement of 
complete response in the training set (area under curve, 
AUC, 0.81, p = 0.0078). Thus, a cut-off level of 200 ng/
mL for s-Arg-1 was chosen to predict response status at 
24 months (Table 2).
In the validation set, baseline levels of s-Arg-1 > 
200 ng/mL resulted in 73% (C.I. 95% 60–84) sensitivity 
Figure 1: Neutrophils are dysfunctional in HL. Mean values ± DS of phagocytosis test in neutrophils are shown from HL patients 
and healthy subjects in duplicate (panel A). Mean fluorescence intensity (MFI) of CD11b in neutrophils was evaluated at diagnosis (panel B) 
and after 2 courses of ABVD therapy (panel C). Neutrophils isolated from 4 healthy donors in two independent experiments were incubated 
for 24 hours with RPMI media plus 20% of serum obtained from healthy donor or HL patients in order to evaluate any change in CD11b 
MFI (panel D). Gating strategy for CD11b expression on neutrophils is shown in (panel E).
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and 83% (C.I. 95% 59–96) specificity in predicting 
response status at 24 months follow-up. Since the PET-
2-oriented therapeutic approach, we evaluated also the 
ability of s-Arg-1 to predict PET-2 status, as reported in 
Table 2.
In the validation set, patients with high s-Arg-1 had 
shorter PFS at 24 months than patients with low Arg-1 
(56.2% vs 93.4%, p < 0.0001, Supplementary Figure 4A), 
similarly to what described based on PET-2 status (28.7% 
vs 88.9 %, p < 0.0001, Supplementary Figure 4B). 
Thus, in the whole cohort of 118 patients, PFS at 36 
months was 89.8% for patients with low s-Arg-1 versus 
55.5% in patients with high s-Arg-1 (Figure 5A). Based 
on PET-2 scan, PFS at 36 months was 83.3% in patients 
with negative scan and 53.2% in patients with positive 
scan, despite an early salvage treatment in patients with 
positive PET-2 scan (Figure 5B). In the group of PET-2 
negative patients (N = 97), PFS at 36 months was 95.6% 
for patients with low s-Arg-1 (n = 69) versus 68.7% in 
patients with high s-Arg-1 (N = 18, p = 0.001, Figure 5C). 
In multivariate analysis, PET-2 and s-Arg-1 at 
diagnosis were the only significant prognostic variables 
(respectively p = 0.0004 and p = 0.012, Table 3), despite 
the limited size of the sample and the adopted therapeutic 
strategy including early shift to BEACOPP treatment in 
case of PET-2 positivity.
With these two prognostic variables, we were able 
to define three distinct groups of patients based on PET-2 
status after two cycles of chemotherapy and s-Arg-1 level 
at diagnosis. Figure 5D shows the PFS curves in patients 
with low s-Arg-1 and negative PET-2 scan (score 0, N = 
63, 53%) or at least one unfavourable prognostic factors 
(score 1, N = 46, 40%) or high s-Arg-1 and positive PET-2 
(score 2, N = 9, 7%). 
Patients with score 0 had 89.5% PFS at 36 months 
versus 67.6% for patients with score 1 versus 37% for 
patients with score 2 (p = 0.0004).
DISCUSSION
We previously showed that MDSC are increased in 
HL and have a prognostic role [17]. We therefore focused 
on neutrophils since neutrophilia is a common clinical 
finding in HL, and together with a low lymphocytes count 
Figure 2: Immunosuppressive effect of HL neutrophils on T-cells can be reverted by nor-NOHA. Results at 48 hours are 
reported separately for activation marker expression of CD69 (A), CD71 (B), HLA-DR (C) and proliferation (D) in h-Ly co-cultured with 
HL-N in absence (white bars) or in presence of 200 μM nor-NOHA (grey bars). Results represent MFI mean ± SD of duplicates from four 
donors and four patients, and are representative of three independent experiments. 
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Table 2: Arg-1 at diagnosis can predict early (PET-2 status) and long term (relapse/refractory 
disease at 24 months follow-up) outcome of HL patients
Training set (n = 40) Validation set (n = 78)
Complete 
remission @ 
24 months
(N 32)
Relapse/
Refractory disease
(N 8)
R/R status @ 
24 months
Complete remission 
@ 
24 months
(N 60)
Relapse/
Refractory disease
(N 18)
R/R status @ 
24 months 
Arg-1 
< 200 ng/mL
28 3 p = 0.0078
Sensitivity
87 % (71–96)
Specificity
62 % (25–92)
PPV
90 % (74–98)
NPV
56 % (21–86)
44 3 p < 0.0001
Sensitivity
73 % (60–84)
Specificity
83 % (59–96)
PPV
93 % (82–98)
NPV
48 % (30–66)
Arg-1 
≥ 200 ng/mL
4 5 16 15
Complete 
remission @ 
24 months
(N 32)
Relapse/
Refractory disease
(N 8)
R/R status @ 
24 months
Complete remission 
@ 
24 months
(N 60)
Relapse/
Refractory disease
(N 18)
R/R status @ 
24 months 
Negative scan 30 4 p = 0.009
Sensitivity
93 % (79–99)
Specificity
50 % (16–84)
PPV
88 % (73–96)
NPV
67 % (23–95)
55 8 p < 0.0001
Sensitivity
92 % (82–97)
Specificity
56 % (31–78)
PPV
87 % (77–94)
NPV
67 % (38–88)
Positive 
scan
2 4 5 10
Negative scan
(N 34)
Positive scan
(N 6)
PET-2 status Negative scan
(N 63)
Positive scan
(N 15)
PET-2 status
Arg-1 
< 200 ng/mL
30 1 p = 0.01
Sensitivity
88 % (73–96)
Specificity
83 % (36–99)
PPV
96 % (85–99)
NPV
56 % (21–86)
42 5 p = 0.03
Sensitivity
67 % (54–78)
Specificity
67 % (39–88)
PPV
89 % (76–96)
NPV
33 % (16–51)
Arg-1 
≥200 ng/mL
4 5 21 10
We reported sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) in the training and validation set for Arg-1 as 
biomarker predictive of PFS at 24 months. 95% confidence interval are reported in round brackets.
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Figure 3: Arg-1 expression in neutrophils and lymph-node microenvironment. Neutrophils isolated from control and 
HL patients were analysed for Arg-1 expression (A), activity by measuring urea (B) and protein expression by Western Blot (C). All 
assays were performed in triplicate. Representative microphotographs relative to Arg-1 in situ immunohistochemical detection in a case 
of mixed cellularity cHL (D), nodular sclerosis cHL (E), and in a lymph-node with reactive follicular hyperplasia (F). Double-marker 
immunofluorescence revealing that Arg-1+ cells within cHL environment were positive for CD68 (clone KP1, G upper panels) and IDO 
(Figure 3H–3I) (20 and 40× magnification).Abbreviations: CTRL-N: pool of neutrophils from healthy subjects; HL-N: pool of neutrophils 
from Hodgkin`s Lymphoma at diagnosis; Arg-1: Arginase 1
Figure 4: s-Arg-1 is increased in HL. Concentration of arginase in serum (s-Arg-1) is reported for healthy volunteers and HL patients 
at diagnosis (panel A). Reduction in s-Arg-1 occurred by first two months of ABVD treatment, deeper at the end of planned treatment (B), 
except for PET-2 positive (panel C) or non-responder patients (panel D).
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is associated with a poor prognosis [9]. The imbalance 
between myeloid and lymphoid arm has been proposed as 
an additional biomarker in HL, including the ratio between 
the absolute counts of monocytes and lymphocytes [33]. 
However, the prognostic value of all the above markers 
was superseded by PET-2 [4].
In this work we investigated the function of 
neutrophils isolated from patients affected by HL sorted by 
physical methods. We found that N-HL are dysfunctional, 
since they exhibit a reduced phagocytic activity despite 
presence of activation signalling as shown by high 
levels of CD11b on the surface, as consequence of a 
sterile chronic inflammation leaded by soluble factors in 
HL including TGF-beta and IL-6 [34]. This uncoupled 
stimulation is likely due to one or more soluble factor(s) 
deserving specific investigation in further works.
We demonstrated that neutrophils of HL 
patients are able to reduce CD3ζ expression and other 
activation markers on the cell surface of T-lymphocytes 
stimulated with PHA-P (Figure 2), pointing toward 
an immunosuppressive activity of N-HL on normal 
lymphocytes. Downregulation of CD3ζ is a frequent 
mechanism of immunosuppression occurring in patients 
with solid cancers [19, 35–37]. The inflammatory 
Table 3: Cox proportional hazard regression analysis
Variable HR 95%CI for HR p-value
PET-2 4.6 2.1–10.8 0.0004
WBC > 15,000 cells/uL 1.6 0.28–13.3 0.58
s-Arg-1 3.3 1.3–8.4 0.01
B-symptoms 1.8 0.32–12.3 0.62
Abbreviations: HR hazard ratio, WBC: white blood cells.
Figure 5: Progression free survival based on combination of PET-2 status and s-Arg-1 level. Kaplan-Meier curves of 
progression free survival based on s-Arg-1 at diagnosis (panel A) and PET-2 scan (panel B) in the whole cohort of 118 patients are shown. 
Progression free survival in the cohort of patients carrying negative PET-2 based on s-Arg-1 is shown in (panel C). A score was developed 
based on PET-2 status after two cycles of chemotherapy and s-Arg-1 level at diagnosis (Panel D). Patients with low s-Arg-1 and negative 
PET-2 scan had score 0, patients with high s-Arg-1 or positive PET-2 scan had score 1 and patients with high s-Arg-1 and positive PET-2 
scan had score 2.
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environment may contribute to the accumulation of 
both mature neutrophils and MDSC. PMN from healthy 
donors activated with N-formil-L-methyonil-L-leucyl-L-
phenylalanine co-purify with PBMC and suppress T-cells 
in a dose-dependent manner [38], similarly to mature 
neutrophils isolated from patients affected by sepsis [39] 
or mature neutrophils isolated from volunteers treated with 
LPS [34]. In absence of reliable markers to distinguish in 
human between normal mature neutrophils and G-MDSC, 
we hypothesized that aberrant function of HL-N could 
be due to a chronic stimulation (as suggested by CD11b 
expression) to sequentially downregulated T-cell function 
and inhibited effector responses during the transition to 
memory cells [40]. Indeed, we hypothesized that this 
immunosuppressive activity is mediated by Arg-1. 
Arg-1 is contained in neutrophils, at the level of 
cytoplasmic azurophil granules as reported in most cases 
[24, 26, 41] but also in gelatinase grains [25]. Arg-1 
modifies the metabolism of L-arginine, including the de-
phosphorylation of cofilin, which is needed for the stability 
of the immunological synapse [42] and downregulates the 
CD3ζ chain translation in T cells, contributing to inhibit T 
cell proliferation [19, 22, 29–31]. 
In our study on neutrophil functional activity we 
showed that HL-N are characterised both by increased 
levels and activity of Arg-1 compared to healthy subjects 
(Figure 3). This is probably responsible for the increased 
Arg-1 serum levels that we have found in HL patients. 
In particular, s-Arg-1 levels proved higher in the serum 
of HL patients at diagnosis and promptly decreased upon 
effective treatment.
In both training and validation sets we found that 
Arg-1 is correlated to clinical features at baseline (stage, 
B symptoms, and elevated ESR). Most important, an 
Arg-1 serum level > 200 ng/mL at diagnosis represents a 
negative prognostic factor, able to predict response status 
at 24 months. In addition, we found that Arg-1 in some 
extend is able to predict PET-2 positivity, which remains, 
according to several recent reports the most important 
predictive factor on treatment outcome [3, 43–45]. This 
assumption has been also confirmed by our data, showing 
that a positive PET-2 may indeed identify patients 
candidate to a more aggressive treatment [45]. 
However, PET-2 information is available only 
during treatment and biological mechanisms leading 
to chemo-resistance may be activated as early as after 
2 cycles of ABVD treatment. On the contrary, s-Arg-1 
is a true prognostic factor, readily available at baseline 
before treatment onset, giving information that can be 
extremely useful for clinicians. Alternatively, it could be 
used as complementary information together with PET-2. 
Indeed, we found that Arg-1 and PET-2 can be combined 
in a prognostic score with three different probabilities of 
outcome. 
In the last years, many studies have indicated the 
prognostic role in HL of serum cytokines, such as soluble 
CD30, IL-6, Il-2R or activation-related chemokine 
(TARC) [46]. However, different from the latter, Arg-
1 is a specific marker of tumour functional activity as it 
portrays the T-lymphocyte suppression by HL. Future 
studies should explore the relationship of Arg-1 with 
other significant cytokines in HL to define a “cytokine 
fingerprint” in a single-patient basis with a strong potential 
prognostic impact.
In HL lymph nodes, high number of Arg-1+myeloid 
cells are significantly associated to shorter progression 
free survival in early stage patients and are correlated 
with a worse overall survival. In particular, a fraction 
of CD68KP1+ elements do also express Arg-1 in 
immunofluorescence [47]. Whether the prognostic value 
of MDSC Arg-1+ overlaps with that of TAM CD68KP1+ 
in HL [11] is still under investigation.
In conclusion, s-Arg-1 levels higher than 200 ng/mL 
are associated to a shorter PFS in HL. This observation 
needs to be prospectively confirmed in a larger series of 
patients.
MATERIALS AND METHODS
Patients
Peripheral blood samples were prospectively 
collected from 118 consecutive newly diagnosed patients 
treated at the Division of Haematology, AOU Policlinico-
OVE, University of Catania between August 2012 and 
June 2014. First 40 cases were defined as training set 
(since these samples were used for functional evaluations), 
and further 78 patients considered as validation set. Thirty-
five healthy subjects were evaluated as controls. The study 
was approved by the local IRB. All participants signed a 
written informed consent in accord to the Declaration of 
Helsinki.
The advanced-stage patients included in the present 
study were enrolled in the prospective multicenter phase II 
clinical trial HD 0607, as elsewhere reported [8]. Briefly, 
treatment started with 2 ABVD cycles [48, 49] and an 
interim PET (PET-2) was performed afterwards. On the 
basis of PET-2 results, patients with a positive scan shifted 
to a more aggressive treatment with BEACOPP regimen 
(bleomycin, etoposide, doxorubicin, cyclophosphamide, 
vincristine, procarbazine, and prednisone), four escalated 
+ four baseline cycles; patients with a negative PET-
2 continued with standard ABVD treatment [8]. Early 
stage patients received two or four courses of ABVD 
chemotherapy plus involved field radiotherapy as 
clinically indicated. 
FDG-PET scan assessment 
Both baseline and interim PET were performed 
using standard scanning protocol. The scans were acquired 
at 60 ± 10’ (early) after the injection of the tracer and a 
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semi-quantitative Deauville score was attributed to each 
image; scans were centrally reviewed by a panel of 
nuclear medicine experts in the HD 0607 trial, and by 
two local reviewers in early stage (I-IIA) disease [50, 51]. 
Only frankly positive and minimally positive scans 
were reviewed. A minimally positive scan was defined 
as any scan with any residual FDG uptake outside the 
physiological areas of the tracer concentration (mediastinal 
blood pool and liver) [43]. 
Reagents
Ficoll-Paque was obtained from Pharmacia LKB 
Biotechnology. Heat inactivated/gamma-irradiated 
fetal bovine serum was obtained from Gibco Industries 
(Carlsbad, Ca). RPMI 1640 media with L-glutamine (1x), 
Dulbecco’s phosphate-buffered saline (D-PBS) were 
purchased from Celbio, Italy and phytohemagglutinin 
(PHA-P) was obtained from Sigma-Aldrich (St. Louis, 
MO, USA).
The following anti-human antibodies were 
purchased from Beckman Coulter: HLA-DR- PC5 (Clone 
Immu-357), CD45 PC5 (clone J.33), CD15 PE (clone 
80H5), CD3 ECD (clone UCHT1), HLA-DR- PC5 (Clone 
Immu-357), CD69 PE (clone TP1.55.3), CD71 FITC 
(clone DYJ1.2.2), CD11b FITC (clone Bear1) while 
CD3ζ/CD247 PE (clone 6B10.2) was purchased from 
eBioscience. Fluorescent-labeled isotype matched control 
antibodies were also purchased from Beckman Coulter, 
used as negative controls.
Phagocytosis assay
Phagocytic activity of myeloid compartment 
was detected using the Phagotest kit (Opregen Pharma, 
Heidelberg, Germany). 
Briefly, 100 µl heparinized whole peripheral 
blood is incubated with 20 µl opsonized FITC-labeled 
Escherichia coli for 10 min at 37°C in a water bath and 
in parallel a negative control sample remained on ice. 
The phagocytosis was stopped by placing the samples on 
ice. To eliminate the fluorescence of non-phagocytized 
bacteria, 100 μl of quenching solution were added. After 
a wash with 3 ml of washing solution (5 min, 250 × g, 
4°C), the cells were incubated for 10 min on ice in 200 μl 
of DNA and analyzed by flow cytometry using a Coulter 
EPICS-XL-MCL cytometer. 
Neutrophils were gated through the scatter 
parameters (forward, FCS vs side, SSC) and their green 
fluorescence histogram was analyzed. The phagocytic 
ability was expressed as percentage of fluorescent cells in 
the population studied and calculated by subtracting the 
percentage of the negative control sample (< 1%) from 
the positive sample.
Isolation of Neutrophils and Lymphocytes
Whole blood (40 ml) was collected from healthy 
volunteers and HL patients in EDTA vacutainer tubes 
and diluted 1:1 with Dulbecco’s phosphate buffered 
saline (PBS) (Celbio). Peripheral blood mononuclear 
cells (PBMC) were then isolated by density gradient 
centrifugation with Ficoll-Paque (Pharmacia LKB 
Biotechnology). 
The resulting layer from the gradient was diluted 
and washed twice with PBS to obtain PBMC from the 
top and neutrophils from the bottom. T-lymphocytes 
were isolated using T-cells enrichment columns (R&D 
Systems) and their purity (> 90%) was assessed using flow 
cytometry. 
To isolate neutrophils, the high-density layer was 
subjected to hypotonic lysis (155 mM NH4 Cl, 10 mM 
KHCO3, 0.1 mM EDTA, pH 7.4) for 15 minutes on ice. 
After washing, cell purity and viability were checked by 
flow cytometry (Supplementary Figure 1) and microscopy. 
PMNs showed a purity and viability of more than 90%.
Evaluation of suppressive activity of neutrophils 
To evaluate the suppressive activity of neutrophils, 
we assessed their ability to inhibit both proliferation and 
activation of T lymphocytes.
T- cell proliferation
5 × 105 of the T-lymphocytes isolated from 5 healthy 
donors were labelled with 1 µM of Carboxyfluorescein 
succinimidyl ester (CFSE) (BD Pharmingen) at 37°C for 
20 min, then added to a 24-well tissue culture plate in 
the presence of phytohaemagglutinin (PHA-P, 5 mg/ml) 
(Sigma-Aldrich) and co-cultured with neutrophils (N) 
obtained from 8 HL or 5 healthy subjects (matched for 
sex and age) at ratio 1:2 and 1:8. The T-cell proliferation 
measured by CFSE dilution was evaluated by flow 
cytometry after 72 hours. The experiments were conducted 
in parallel in presence of 200 μM nor-NOHA.
T -cell activation 
In addition, T-lymphocytes from 5 healthy donors 
were harvested, washed twice in staining buffer (PBS 
containing 0.2% BSA and 0.1% sodium azide) and added 
to a 96-well polypropylene plate at concentration 5 × 105 
cells/well. After stimulation with 5 mg/ml PHA they were 
co-cultured with neutrophils (N) obtained from 8 HL or 5 
healthy subjects at ratio 1:2 and 1:8.
Then, at 48 hours, we evaluated the expression on 
T-lymphocytes of some activation markers such as CD69, 
CD71, HLA-DR and CD3ζ. PHA-stimulated T-cells 
were used as control. The experiments were conducted in 
parallel in presence of 200 μM nor-NOHA.
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Staining with respective isotype-matched control 
antibodies was also included for each condition to detect 
nonspecific background staining. 
Density of expression of activation markers (Mean 
Fluorescent Intensity, MFI) were obtained and represented.
Arginase assays
Neutrophils were plated at 5 × 105 per well 
directly ex vivo in 96 well tissue culture plates, and 
washed with PBS and lysed with 0.1% Triton X-100 
containing protease inhibitor (Roche, Nutley, NJ). To 
activate Arg-1, buffer containing Tris-HCl (25 mM) 
and MnCl2 (10 mM) was added and heated to 56°C 
for 10 minutes. L-arginine (0.5 M; Sigma) was added, 
and the samples were heated for 1 hour at 37°C. The 
hydrolysis of arginine was stopped with 800 μL of an 
acid solution mixture (H2SO4:H3PO4:H2O, 1:3:7). 
The amount of urea produced was determined using 9% 
α-isonitrosopropriophenone and compared with a standard 
curve with absorbance measured at 540 nm.
Arg-1 detection by RT-PCR
Total RNA was extracted using TRIzol reagent 
and quantified using UV spectrophotometer. For real-
time PCR analysis of mRNA expression, 1.0 μg of total 
RNA (in 20 μl reaction volume) was reverse transcribed 
using reverse transcriptase (Roche Diagnostic Corp., 
Indianapolis, IN, USA) and oligo-dT primers in a standard 
reaction. The quantitative real-time polymerase chain 
reaction was performed by use of a LightCycler (Roche), 
with primers specifically designed for Arg-1 (Forward:5′-
CTCTAAGGGACAGCCTCGAGGA-3′, Reverse: 
5′-TGGGTTCACTTCCATGATATCTA-3′; Applied 
Biosystem) according to the gene manufacturer’s 
recommended protocol. Each reaction was run in 
triplicate. Samples were quantified accordingly 
(LightCycler analysis software, version 3.5) 
using the housekeeping gene GAPDH (Forward: 
5′-CCAGCCGAGCCACATCGCTC-3′, Reverse: 
5′-ATGAGCCCCAGCCTTCTC-3′; Roche) as standard.
Western blot analysis 
Briefly, for western blot analysis 30 μg of 
protein was loaded onto a 12% polyacrylamide gel 
Mini-PROTEAN® TGX™ (BIO-RAD) followed by 
electrotransfer to nitrocellulose membrane Trans-Blot® 
Turbo™ (BIO-RAD) using Trans-Blot® SD Semi-Dry 
Transfer Cell (BIO-RAD). After blocking, membrane was 
three times washed in PBS for 5 minutes and incubated 
with primary antibodies against Arg-1 (anti-rabbit, Sigma-
HPA003595). Next day, membranes were three times 
washed in PBS for 5 minutes and incubated with the 
secondary antibody FITC (anti-rabbit, Cat. No. sc-2012, 
Santa Cruz Biotechnology) for 1 h at room temperature. 
The blots were visualized using Odyssey Infrared 
Imaging Scanner (Licor) and protein expression levels 
were quantified by densitometric analysis of antibody 
responses. Data were normalized to protein expression 
levels of β-actin. 
Immunohistochemistry and immunofluorescence
Immunohistochemistry was performed on sections 
from four classical Hodgkin’s lymphoma samples (2 
nodular sclerosis and 2 mixed cellularity) and on sections 
from three lymph node samples of reactive follicular 
hyperplasia, using a polymer detection method as 
previously reported [52]. Briefly, tissue samples were 
fixed in 10% buffered formalin and paraffin embedded. 
Four-micrometers-thick sections were deparaffinized 
and rehydrated. The antigen unmasking technique was 
performed using Novocastra Epitope Retrieval Solutions 
pH6, pH 9 and pH 8 in PT Link Dako pre-treatment 
module at 98°C for 30 minutes. 
Subsequently, the sections were brought to room 
temperature and washed in PBS. After neutralization of the 
endogenous peroxidase with 3% H2O2 and Fc blocking by 
a specific protein block (Novocastra UK) the samples were 
incubated over night with the primary polyclonal antibody 
anti-human Arginase 1, 1/200 pH 9 (GeneTex Catalog 
Number GTX109242), at 4°C. Staining was revealed by 
polymer detection kit (Novocastra) and AEC (3-amino-
9-ethylcarbazole) substrate-chromogen. The slides were 
counterstained with Harris hematoxylin (Novocastra). 
For double-marker immunofluorescence analyses, 
two sequential rounds of single immunofluorescence 
staining were performed. The following primary 
antibodies were used: polyclonal anti-human Arginase 1, 
1/200 (GeneTex); monoclonal anti-Human CD68, 1/50 
(clone KP1 Dako Denmark), monoclonal anti-Human 
IDO, 1/100 (clone 10.1, Novus biologicals).
After Fc blocking, primary antibodies binding 
was revealed by fluorochrome-conjugated secondary 
antibodies: Alexa Fluor 488 goat anti-Rabbit IgG (H+L, 
Invitrogen Molecular Probes, Carlsbad, CA), Alexa Fluor 
568 conjugated goat anti-Mouse IgG (H+L, Invitrogen 
Molecular Probes, Carlsbad, CA).
Negative control stainings were performed by using 
rabbit immune serum instead of the primary antibody. 
The slides were counterstained with DAPI Nucleic Acid 
Stain (Invitrogen Molecular Probes). All the sections were 
analyzed under a Zeiss Axioscope A1 optical microscope 
(Zeiss) equipped with fluorescence module and 
microphotographs were collected using a Zeiss Axiocam 
503 color (Zeiss). 
Arginase detection in peripheral blood
For sera collection, blood was centrifuged by 
2 hours at 1600 × g for 10 minutes at room temperature 
and surnatant saved at –80°C for maximum 2 months. 
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Arg-1 was detected in serum of healthy volunteer donors 
and HL patients by a commercial ELISA kit (Biovendor 
CS058) following the manufacturer’s instructions.
Statistical methods
Descriptive statistics were generated for analysis 
of results. Clinical and immunological parameters were 
compared by unpaired t-test. Baseline Arg-1 levels 
were correlated to Ann Arbor stage of disease, presence 
of B-symptoms and bulky disease, extranodal or bone 
marrow involvement and PET-2 status. 
The cut-off of s-Arg-1 to identify patients with 
poor outcome was identified by the receiver operating 
characteristic (ROC) value with both sensitivity 
and specificity more than 70% in the training set to 
discriminate patients in complete remission versus 
refractory/relapsed within 24 months from the last chemo. 
This cut-off was applied in the validation set to compare 
the progression free survival (PFS) at 24 months between 
patients with high or not-high s-Arg-1 levels. 
Progression free survival was calculated 
distinguishing high and not-high s-Arg-1 carrying patients 
according to Kaplan’s Meier method.
Statistical analyses were elaborated through 
GraphPad Prism version 6.00 for Windows, GraphPad 
Software, San Diego California USA, www.graphpad.
com.
ACKNOWLEDGMENTS
The authors thank all patients and nurses who 
contributed to the study, Dr. M. Lo Presti and Dr. 
S. Paratore for technical assistance in performing 
immunohistochemistry assays. This work was supported 
by Associazione Italiana contro le Leucemie (AIL) of 
Catania, Fondazione Catanese per lo Studio e la Cura delle 
Malattie Neoplastiche del Sangue (FON.CA.NE.SA) and 
AIRC (Associazione Italiana per la Ricerca sul Cancro).
CONFLICTS OF INTEREST
The authors declare no competing financial interests.
Authors’ contributions
Conception and design: Alessandra Romano and 
Francesco Di Raimondo
Collection and assembly of data: Piera La Cava, 
Daniele Tibullo, Cesarina Giallongo, Anastasia Laura 
Caruso, Annalisa Chiarenza, Giovanna Motta
Protein assays and imaging: Nunziatina Laura 
Parrinello, Loredana Villari, Claudio Tripodo, Stefano 
Pileri, Sebastiano Cosentino, Massimo Ippolito
Data analysis and interpretation: Alessandra 
Romano, Calogero Vetro, Nunziatina Laura Parrinello, 
Ugo Consoli, Andrea Gallamini, Francesco Di Raimondo
Manuscript writing: All authors
Final approval of manuscript: All authors
REFERENCES
1. Montes-Moreno S. Hodgkin’s Lymphomas: A Tumor 
Recognized by Its Microenvironment. Adv Hematol. 2011; 
2011:142395.
2. Ma Y, Visser L, Roelofsen H, de Vries M, Diepstra A, van 
Imhoff G, van der Wal T, Luinge M, Alvarez-Llamas G, 
Vos H, Poppema S, Vonk R, van den Berg A. Proteomics 
analysis of Hodgkin lymphoma: identification of new 
players involved in the cross-talk between HRS cells and 
infiltrating lymphocytes. Blood. 2008; 111:2339–2346.
3. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, 
Hansen M, Patti C, Loft A, Di Raimondo F, D’Amore F, 
Biggi A, Vitolo U, Stelitano C, et al. Early interim 2-[18F]
fluoro-2-deoxy-D-glucose positron emission tomography is 
prognostically superior to international prognostic score in 
advanced-stage Hodgkin’s lymphoma: a report from a joint 
Italian-Danish study. Journal of clinical oncology. 2007; 
25:3746–3752.
4. Romano A, Vetro C, Donnarumma D, Forte S, Ippolito M, 
Di Raimondo F. Early interim 2-fluoro-2-deoxy-D-glucose 
positron emission tomography is prognostically superior to 
peripheral blood lymphocyte/monocyte ratio at diagnosis 
in classical Hodgkin’s lymphoma. Haematologica. 2012; 
97:e21–23; author reply e24.
5. Gallamini A, Di Raimondo F, La Nasa G, Romano A, 
Borra A, Greco M. Standard therapies versus novel 
therapies in Hodgkin lymphoma. Immunol Lett. 2013.
6. Oki Y, Chuang H, Chasen B, Jessop A, Pan T, Fanale M, 
Dabaja B, Fowler N, Romaguera J, Fayad L, Hagemeister F, 
Alma Rodriguez M, Neelapu S. The prognostic value of 
interim positron emission tomography scan in patients 
with classical Hodgkin lymphoma. British journal of 
haematology. 2014.
7. Biggi A, Gallamini A, Chauvie S, Hutchings M, 
Kostakoglu L, Gregianin M, Meignan M, Malkowski B, 
Hofman MS, Barrington SF. International validation study 
for interim PET in ABVD-treated, advanced-stage hodgkin 
lymphoma: interpretation criteria and concordance rate 
among reviewers. J Nucl Med. 2013; 54:683–690.
8. Gallamini A, Patti C, Viviani S, Rossi A, Fiore F, Di 
Raimondo F, Cantonetti M, Stelitano C, Feldman T, 
Gavarotti P, Sorasio R, Mulè A, Leone M, et al. Early 
chemotherapy intensification with BEACOPP in advanced-
stage Hodgkin lymphoma patients with a interim-PET 
positive after two ABVD courses. British journal of 
haematology. 2011; 152:551–560.
9. Hasenclever D, Diehl V. A prognostic score for advanced 
Hodgkin’s disease. International Prognostic Factors Project 
Oncotarget67345www.impactjournals.com/oncotarget
on Advanced Hodgkin’s Disease. The New England journal 
of medicine. 1998; 339:1506–1514.
10. Moccia AA, Donaldson J, Chhanabhai M, Hoskins PJ, 
Klasa RJ, Savage KJ, Shenkier TN, Slack GW, Skinnider B, 
Gascoyne RD, Connors JM, Sehn LH. International 
Prognostic Score in advanced-stage Hodgkin’s lymphoma: 
altered utility in the modern era. Journal of clinical 
oncology. 2012; 30:3383–3388.
11. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, 
Delaney A, Jones SJ, Iqbal J, Weisenburger DD, Bast MA, 
Rosenwald A, Muller-Hermelink HK, et al. Tumor-
associated macrophages and survival in classic Hodgkin’s 
lymphoma. The New England journal of medicine. 2010; 
362:875–885.
12. Alizadeh D, Trad M, Hanke NT, Larmonier CB, 
Janikashvili N, Bonnotte B, Katsanis E, Larmonier N. 
Doxorubicin Eliminates Myeloid-Derived Suppressor Cells 
and Enhances the Efficacy of Adoptive T Cell Transfer in 
Breast Cancer. Cancer research. 2013.
13. Ko JS, Bukowski RM, Fincke JH. Myeloid-derived 
suppressor cells: a novel therapeutic target. Curr Oncol Rep. 
2009; 11:87–93.
14. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, 
Golshayan A, Rayman PA, Wood L, Garcia J, Dreicer R, 
Bukowski R, Finke JH. Sunitinib mediates reversal of 
myeloid-derived suppressor cell accumulation in renal 
cell carcinoma patients. Clinical cancer research. 2009; 
15:2148–2157.
15. Mantovani A. The growing diversity and spectrum of action 
of myeloid-derived suppressor cells. European journal of 
immunology. 2010; 40:3317–3320.
16. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: 
more mechanisms for inhibiting antitumor immunity. Cancer 
immunology, immunotherapy : CII. 2010; 59:1593–1600.
17. Romano A, Parrinello NL, Vetro C, Forte S, Chiarenza A, 
Figuera A, Motta G, Palumbo GA, Ippolito M, Consoli U, 
Raimondo FD. Circulating myeloid-derived suppressor 
cells correlate with clinical outcome in Hodgkin Lymphoma 
patients treated up-front with a risk-adapted strategy. British 
journal of haematology. 2014.
18. Dumitru CA, Moses K, Trellakis S, Lang S, Brandau S. 
Neutrophils and granulocytic myeloid-derived suppressor 
cells: immunophenotyping, cell biology and clinical 
relevance in human oncology. Cancer immunology, 
immunotherapy : CII. 2012; 61:1155–1167.
19. Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, 
Zabaleta J, Sierra R, Ochoa AC. Arginase I-producing 
myeloid-derived suppressor cells in renal cell carcinoma are 
a subpopulation of activated granulocytes. Cancer research. 
2009; 69:1553–1560.
20. Darcy CJ, Woodberry T, Davis JS, Piera KA, McNeil YR, 
Chen Y, Yeo TW, Weinberg JB, Anstey NM. Increased 
plasma arginase activity in human sepsis: association with 
increased circulating neutrophils. Clin Chem Lab Med. 
2013:1–9.
21. Lechner MG, Megiel C, Russell SM, Bingham B, Arger N, 
Woo T, Epstein AL. Functional characterization of human 
Cd33+ and Cd11b+ myeloid-derived suppressor cell 
subsets induced from peripheral blood mononuclear cells 
co-cultured with a diverse set of human tumor cell lines. 
J Transl Med. 2011; 9:90.
22. Munder M. Arginase: an emerging key player in the 
mammalian immune system. Br J Pharmacol. 2009; 
158:638–651.
23. Raber P, Ochoa AC, Rodriguez PC. Metabolism of 
L-arginine by myeloid-derived suppressor cells in 
cancer: mechanisms of T cell suppression and therapeutic 
perspectives. Immunol Invest. 2012; 41:614–634.
24. Munder M, Mollinedo F, Calafat J, Canchado J, Gil-
Lamaignere C, Fuentes JM, Luckner C, Doschko G, 
Soler G, Eichmann K, Muller FM, Ho AD, Goerner M. 
Arginase I is constitutively expressed in human 
granulocytes and participates in fungicidal activity. Blood. 
2005; 105:2549–2556.
25. Jacobsen LC, Theilgaard-Monch K, Christensen EI, 
Borregaard N. Arginase 1 is expressed in myelocytes/
metamyelocytes and localized in gelatinase granules of 
human neutrophils. Blood. 2007; 109:3084–3087.
26. Rotondo R, Bertolotto M, Barisione G, Astigiano S, 
Mandruzzato S, Ottonello L, Dallegri F, Bronte V, 
Ferrini S, Barbieri O. Exocytosis of azurophil and arginase 
1-containing granules by activated polymorphonuclear 
neutrophils is required to inhibit T lymphocyte proliferation. 
Journal of leukocyte biology. 2011; 89:721–727.
27. Popovic PJ, Zeh HJ, 3rd, Ochoa JB. Arginine and immunity. 
J Nutr. 2007; 137:1681s–1686s.
28. Bronte V. Myeloid-derived suppressor cells in inflammation: 
uncovering cell subsets with enhanced immunosuppressive 
functions. European journal of immunology. 2009; 
39:2670–2672.
29. Hock BD, Taylor KG, Cross NB, Kettle AJ, Hampton MB, 
McKenzie JL. Effect of activated human polymorphonuclear 
leucocytes on T lymphocyte proliferation and viability. 
Immunology. 2012; 137:249–258.
30. Munder M, Schneider H, Luckner C, Giese T, 
Langhans CD, Fuentes JM, Kropf P, Mueller I, Kolb A, 
Modolell M, Ho AD. Suppression of T-cell functions by 
human granulocyte arginase. Blood. 2006; 108:1627–1634.
31. Thewissen M, Damoiseaux J, van de Gaar J, Tervaert JW. 
Neutrophils and T cells: bidirectional effects and functional 
interferences. Molecular immunology. 2011; 48:2094–2101.
32. Choe J-Y, Yun JY, Jeon YK, Kim SH, Park G, Huh JR, Oh S, 
Kim JE. Indoleamine 2,3-dioxygenase (IDO) is frequently 
expressed in stromal cells of Hodgkin lymphoma and is 
associated with adverse clinical features: a retrospective 
cohort study. BMC Cancer. 2014; 14:1–9.
33. Porrata LF, Ristow K, Colgan JP, Habermann TM, 
Witzig TE, Inwards DJ, Ansell SM, Micallef IN, 
Johnston PB, Nowakowski GS, Thompson C, 
Oncotarget67346www.impactjournals.com/oncotarget
Markovic SN. Peripheral blood lymphocyte/monocyte ratio 
at diagnosis and survival in classical Hodgkin’s lymphoma. 
Haematologica. 2012; 97:262–269.
34. Pillay J, Kamp VM, van Hoffen E, Visser T, Tak T, 
Lammers JW, Ulfman LH, Leenen LP, Pickkers P, 
Koenderman L. A subset of neutrophils in human systemic 
inflammation inhibits T cell responses through Mac-1. The 
Journal of clinical investigation. 2012; 122:327–336.
35. Rodriguez P, Zea A, Culotta K, Zabaleta J, Ochoa J, 
Ochoa A. Regulation of T cell receptor CD3zeta chain 
expression by L-arginine. The Journal of biological 
chemistry. 2002; 277:21123–21129.
36. Gunji Y, Hori S, Aoe T, Asano T, Ochiai T, Isono K, Saito T. 
High frequency of cancer patients with abnormal assembly 
of the T cell receptor-CD3 complex in peripheral blood T 
lymphocytes. Japanese journal of cancer research : Gann. 
1994; 85:1189–1192.
37. Finke JH, Zea AH, Stanley J, Longo DL, Mizoguchi H, 
Tubbs RR, Wiltrout RH, O’Shea JJ, Kudoh S, Klein E, 
et al. Loss of T-cell receptor zeta chain and p56lck in T-cells 
infiltrating human renal cell carcinoma. Cancer research. 
1993; 53:5613–5616.
38. Schmielau J, Finn OJ. Activated granulocytes and 
granulocyte-derived hydrogen peroxide are the underlying 
mechanism of suppression of t-cell function in advanced 
cancer patients. Cancer research. 2001; 61:4756–4760.
39. Darcy CJ, Minigo G, Piera KA, Davis JS, McNeil YR, 
Chen Y, Volkheimer AD, Weinberg JB, Anstey NM, 
Woodberry T. Neutrophils with myeloid derived suppressor 
function deplete arginine and constrain T cell function in 
septic shock patients. Critical care (London, England). 
2014; 18:R163.
40. Valitutti S, Muller S, Dessing M, Lanzavecchia A. Signal 
extinction and T cell repolarization in T helper cell-
antigen-presenting cell conjugates. European journal of 
immunology. 1996; 26:2012–2016.
41. Sippel TR, White J, Nag K, Tsvankin V, Klaassen M, 
Kleinschmidt-DeMasters BK and Waziri A. Neutrophil 
degranulation and immunosuppression in patients with 
GBM: restoration of cellular immune function by targeting 
arginase I. Clinical cancer research. 2011; 17:6992–7002.
42. Feldmeyer N, Wabnitz G, Leicht S, Luckner-Minden C, 
Schiller M, Franz T, Conradi R, Kropf P, Muller I, Ho AD, 
Samstag Y and Munder M. Arginine deficiency leads to 
impaired cofilin dephosphorylation in activated human T 
lymphocytes. International immunology. 2012; 24:303–313.
43. Gallamini A. Positron emission tomography scanning: a 
new paradigm for the management of Hodgkin’s lymphoma. 
Haematologica. 2010; 95:1046–1048.
44. Rigacci L, Puccini B, Zinzani PL, Biggi A, Castagnoli A, 
Merli F, Balzarotti M, Stelitano C, Spina M, Vitolo U, 
Stefoni V, Levis A, Gotti M, et al. The prognostic value of 
positron emission tomography performed after two courses 
(INTERIM-PET) of standard therapy on treatment outcome 
in early stage Hodgkin lymphoma: A multicentric study by 
the fondazione italiana linfomi (FIL). American journal of 
hematology. 2015; 90:499–503.
45. Zinzani PL, Broccoli A, Gioia DM, Castagnoli A, 
Ciccone G, Evangelista A, Santoro A, Ricardi U, 
Bonfichi M, Brusamolino E, Rossi G, Anastasia A, Zaja F, 
et al. Interim Positron Emission Tomography Response-
Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: 
Final Results of the Phase II Part of the HD0801 Study. 
Journal of clinical oncology. 2016.
46. Marri PR, Hodge LS, Maurer MJ, Ziesmer SC, Slager SL, 
Habermann TM, Link BK, Cerhan JR, Novak AJ, 
Ansell SM. Prognostic significance of pretreatment serum 
cytokines in classical Hodgkin lymphoma. Clinical cancer 
research. 2013; 19:6812–6819.
47. Gallamini A AC, Tripodo C, et al. 9th International 
Symposium on Hodgkin Lymphoma Cologne, Germany, 
October 12–15, 2013. Haematologica. 2013; 98:1–64.
48. Bonfante V, Santoro A, Viviani S, Valagussa P, 
Bonadonna G. ABVD in the treatment of Hodgkin’s disease. 
Semin Oncol. 1992; 19:38–44; discussion 44-35.
49. Santoro A, Bonadonna G. Prolonged disease-free survival 
in MOPP-resistant Hodgkin’s disease after treatment 
with adriamycin, bleomycin, vinblastine and dacarbazine 
(ABVD). Cancer Chemother Pharmacol. 1979; 2:101–105.
50. Barrington SF, Qian W, Somer EJ, Franceschetto A, 
Bagni B, Brun E, Almquist H, Loft A, Højgaard L, Federico 
M, Gallamini A, Smith P, Johnson P. Concordance between 
four European centres of PET reporting criteria designed for 
use in multicentre trials in Hodgkin lymphoma. Eur J Nucl 
Med Mol Imaging. 2010; 37:1824–1833.
51. Meignan M, Gallamini A, Itti E, Barrington S, Haioun C, 
Polliack A. Report on the Third International Workshop on 
Interim Positron Emission. Leukemia & lymphoma. 2012; 
53:1876–1881.
52. Tripodo C, Sangaletti S, Guarnotta C, Piccaluga PP, 
Cacciatore M, Giuliano M, Franco G, Chiodoni C, 
Sciandra M, Miotti S, Calvaruso G, Care A, Florena AM, 
et al. Stromal SPARC contributes to the detrimental fibrotic 
changes associated with myeloproliferation whereas its 
deficiency favors myeloid cell expansion. Blood. 2012; 
120:3541–3554.
